From move 37 to drug design

At this year’s RAAIS, Max Jaderberg of Isomorphic Labs delivered a talk that felt like the spiritual sequel to AlphaGo, only this time the board isn’t 19×19, it’s the human body. The stakes? The future of drug discovery and human health.Isomorphic Labs, the biotech spinout from DeepMind, has declared a radical mission: solving disease. It's not a metaphor. It’s a systems-level wager that the same kinds of models that cracked Go can crack biology. Not only by digitizing wet labs, but by encoding the dynamics of biomolecules into machine-learnable substrates. If AlphaGo marked the start of AI systems inventing strategies never before seen in human play, Isomorphic wants AI to invent medicines we’d never stumble across in the lab.This is a moonshot, a bet that biology is information science, and machine learning is our best bet at learning its language.